The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of zoledronic acid therapy–associated severe hypophosphatemia to identify poor-prognosis patients with metastatic castration-resistant prostate cancer.
Julia Warr
No relevant relationships to disclose
David Yam
No relevant relationships to disclose
Shannon Goodall
No relevant relationships to disclose
Leah VanDraanen
No relevant relationships to disclose
Angie Giotis
No relevant relationships to disclose
Mark Pasetka
No relevant relationships to disclose
Carlo De Angelis
No relevant relationships to disclose
Urban Emmenegger
No relevant relationships to disclose